SCHEMBL1889395

SCHEMBL1889395

Nc1ncnc2c1ncn2[C@H]1C[C@H](O)[C@@H](COC(=O)CO)O1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.64
ENPP1 P22413 3/20 0.63
P2RY1 P47900 2/20 0.63
HIF1A Q16665 1/20 0.53
PDE4D Q08499 2/20 0.52
PDE3A Q14432 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
PNP P00491 1/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
HTT P42858 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
ADA P00813 1/20 0.50
NT5E P21589 1/20 0.49
DNPH1 O43598 1/20 0.49
PRKAB2 O43741 1/20 0.49
TRPM2 O94759 1/20 0.49
LDHA P00338 1/20 0.49
ADRB2 P07550 1/20 0.49
FBP1 P09467 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8058699 0.92 POLB (0.64) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL2691352 0.90 POLB (0.62) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL6833492 0.89 POLB (0.66) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL3259692 0.89 POLB (0.65) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL8623380 0.89 POLB (0.65) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL5369306 0.88 POLB (0.59) POLBENPP1P2RY1HIF1AAHCY
SCHEMBL3470715 0.87 POLB (0.63) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL7133529 0.87 POLB (0.59) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL4625882 0.86 POLB (0.62) POLBENPP1P2RY1HIF1APDE4D
SCHEMBL5358012 0.86 POLB (0.58) POLBENPP1P2RY1AHCY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242087-B2 Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) 2012-08-14 US disclosed
US-20110112046-A9 PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2011-05-12 US disclosed
US-20100093656-A1 PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112046-A9 PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS MTAP, POLRMT, PNP POLB 12/4885ENPP1 17/4885P2RY1 575/4885
US-20100093656-A1 PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS MTAP, POLRMT, PNP POLB 12/4885ENPP1 17/4885P2RY1 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.